Patents by Inventor Qiyong Peter Liu
Qiyong Peter Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240167022Abstract: Described herein are compositions and methods for treating cancer comprising single-stranded 5? uncapped triphosphate or biphosphate modified RNA oligonucleotides complementary to a miRNA which is highly expressed in a tumor microenvironment in comparison to a non-tumor environment.Type: ApplicationFiled: December 29, 2021Publication date: May 23, 2024Inventors: Robert Michael Dudley, Qiyong Peter Liu, Subrata Kumar Ghosh
-
Patent number: 11975274Abstract: The present invention relates to a spray dried plasma composition having one or more of the following characteristics: when reconstituted, largely amorphous and has no cholesterol crystals; when reconstituted, the number of large particulates is reduced; has low residual moisture; reconstitutes rapidly in under four minutes; highly stable when stored under refrigeration, at room temperature or at elevated temperatures and allows for storage for longer periods of time; when reconstituted, exhibits recovery of the most fragile of proteins, including von Willebrand's factor; when reconstituted with Sterile Water for Injection (SWFI), reconstituted plasma is at a pH that is near normal plasma pH, and does so without treatment or storage in CO2 or other pH adjustment; and when reconstituted, has reduced complement activation (C5A, C3A).Type: GrantFiled: September 15, 2022Date of Patent: May 7, 2024Assignee: Velico Medical, Inc.Inventors: Qiyong Peter Liu, Herman E. Snyder, Kyle D. Erickson, Evan P. Ordway, William J. Merritt, Richard Meehan, Robert R. Andrews, Clair Strohl, Jihae Sohn, Mark A. Popovsky, Lisa A. Buckley
-
Publication number: 20240131063Abstract: The present invention relates to a spray dried plasma composition having one or more of the following characteristics: when reconstituted, largely amorphous and has no cholesterol crystals; when reconstituted, the mean size of large particulates is reduced; has low residual moisture; reconstitutes rapidly in under four minutes; highly stable when stored under refrigeration, at room temperature or at elevated temperatures and allows for storage for longer periods of time; when reconstituted, exhibits recovery of the most fragile of proteins, including von Willebrand's factor; when reconstituted with Sterile Water for Injection (SWFI), reconstituted plasma is at a pH that is near normal plasma pH, and does so without treatment or storage in CO2 or other pH adjustment.Type: ApplicationFiled: September 14, 2023Publication date: April 25, 2024Applicant: Velico Medical, Inc.Inventors: Jihae Sohn, Lisa A. Buckley, Mark A. Popovsky, Qiyong Peter Liu, Herman E. Snyder, Evan P. Ordway, William J. Merritt, Robert R. Andrews, Clair Strohl
-
Publication number: 20240131062Abstract: The spray dried plasma by the nature of its characteristics and the process by which it is made allows for a dried plasma with reduced pathogens. It has at least three aspects of pathogen reduction that results in a plasma product with reduced or no pathogens. The first aspect relates to a spray drying disposable and machine that eliminates or minimizes the introduction of pathogens into the spray drying process and is referred to as the anti-contamination process. The second aspect of pathogen reduction relates to the spray drying process and parameters that reduces pathogens that may be present in the donor plasma, and/or inhibit pathogen growth and/or pathogen proliferation introduced by the donor plasma. The third aspect results in reduced pathogens occurring during storage of the dried plasma wherein the manufacturing and storage conditions are such that pathogens are reduced, and/or pathogen growth and/or pathogen proliferation are inhibited.Type: ApplicationFiled: September 14, 2023Publication date: April 25, 2024Applicant: Velico Medical, Inc.Inventors: Mark A. Popovsky, Lisa A. Buckley, Jihae Sohn, Evan P. Ordway, Qiyong Peter Liu, Robert R. Andrews, Herman E. Snyder, William J. Merritt, Clair Strohl, Russell J Barron
-
Publication number: 20240123368Abstract: The present invention relates to a spray dried plasma composition having one or more of the following characteristics: when reconstituted, largely amorphous and has no cholesterol crystals; when reconstituted, the number of large particulates is reduced; has low residual moisture; reconstitutes rapidly in under four minutes; highly stable when stored under refrigeration, at room temperature or at elevated temperatures and allows for storage for longer periods of time; when reconstituted, exhibits recovery of the most fragile of proteins, including von Willebrand's factor; when reconstituted with Sterile Water for Injection (SWFI), reconstituted plasma is at a pH that is near normal plasma pH, and does so without treatment or storage in CO2 or other pH adjustment; and when reconstituted, has reduced complement activation (C5A, C3A).Type: ApplicationFiled: January 17, 2023Publication date: April 18, 2024Applicant: Velico Medical, Inc.Inventors: Robert R. Andrews, Herman E. Snyder, William J. Merritt, Evan P. Ordway, Clair Strohl, Qiyong Peter Liu, Jihae Sohn
-
Publication number: 20240109000Abstract: The present invention relates to a spray dried plasma composition having one or more of the following characteristics: when reconstituted, largely amorphous and has no cholesterol crystals; when reconstituted, the number of large particulates is reduced; has low residual moisture; reconstitutes rapidly in under four minutes; highly stable when stored under refrigeration, at room temperature or at elevated temperatures and allows for storage for longer periods of time; when reconstituted, exhibits recovery of the most fragile of proteins, including von Willebrand's factor; when reconstituted with Sterile Water for Injection (SWFI), reconstituted plasma is at a pH that is near normal plasma pH, and does so without treatment or storage in CO2 or other pH adjustment; and when reconstituted, has reduced complement activation (C5A, C3A).Type: ApplicationFiled: September 15, 2022Publication date: April 4, 2024Applicant: Velico Medical, Inc.Inventors: Qiyong Peter Liu, Herman E. Snyder, Kyle D. Erickson, Evan P. Ordway, William J. Merritt, Richard Meehan, Robert R. Andrews, Clair Strohl, Jihae Sohn
-
Publication number: 20240091666Abstract: The present invention relates to a spray dried plasma composition having one or more of the following characteristics: when reconstituted, largely amorphous and has no cholesterol crystals; when reconstituted, the number of large particulates is reduced; has low residual moisture; reconstitutes rapidly in under four minutes; highly stable when stored under refrigeration, at room temperature or at elevated temperatures and allows for storage for longer periods of time; when reconstituted, exhibits recovery of the most fragile of proteins, including von Willebrand's factor; when reconstituted with Sterile Water for Injection (SWFI), reconstituted plasma is at a pH that is near normal plasma pH, and does so without treatment or storage in CO2 or other pH adjustment; and when reconstituted, has reduced complement activation (C5A, C3A).Type: ApplicationFiled: January 17, 2023Publication date: March 21, 2024Applicant: Velico Medical, Inc.Inventors: Richard Meehan, Robert R. Andrews, Herman E. Snyder, William J. Merritt, Evan P. Ordway, Clair Strohl, Qiyong Peter Liu, Jihae Sohn
-
Publication number: 20240091155Abstract: A method of treating plasma with a pretreatment solution that has a physiologically compatible spray dry stable acidic substance (SDSAS) and an amino acid, prior to or contemporaneously with spray drying of the plasma that results in greater recovery and greater long-term stabilization of the dried plasma proteins as compared to spray dried plasma that has not be subject to the formulation method of the present invention, as well as compositions related to plasma dried by the methods of the present invention.Type: ApplicationFiled: September 15, 2022Publication date: March 21, 2024Applicant: Velico Medical, Inc.Inventors: Qiyong Peter Liu, William J. Merritt, Jihae Sohn
-
Publication number: 20240091667Abstract: A method of treating plasma with a pretreatment solution that has a physiologically compatible spray dry stable acidic substance (SDSAS) and an amino acid, prior to or contemporaneously with spray drying of the plasma that results in greater recovery and greater long-term stabilization of the dried plasma proteins as compared to spray dried plasma that has not be subject to the formulation method of the present invention, as well as compositions related to plasma dried by the methods of the present invention.Type: ApplicationFiled: September 14, 2023Publication date: March 21, 2024Applicant: Velico Medical, Inc.Inventors: Lisa A. Buckley, Mark A. Popovsky, Jihae Sohn, Qiyong Peter Liu, William J. Merritt
-
Publication number: 20240042070Abstract: Described herein are compositions and methods for treating cancer using a RIG-I agonist precursor comprising single-stranded 5? uncapped triphosphate or biphosphate antisense oligonucleotide having a sequence complementary to an endogenous miRNA; optionally wherein the compositions and methods comprise a nanoparticle for targeted delivery of the RIG-I agonist precursor and a radiolabel to a tumor micro environment.Type: ApplicationFiled: June 28, 2023Publication date: February 8, 2024Inventors: Robert Michael Dudley, Qiyong Peter Liu, Dustan Bonnin, Subrata Kumar Ghosh
-
Patent number: 11806431Abstract: A method of treatment of plasma with a physiologically compatible spray dry stable acidic substance (SDSAS) prior to or contemporaneously with spray drying of the plasma that results in greater recovery and greater long-term stabilization of the dried plasma proteins as compared to spray dried plasma that has not be subject to the formulation method of the present invention, as well as compositions related to plasma dried by the methods of the present invention.Type: GrantFiled: June 2, 2021Date of Patent: November 7, 2023Assignee: Velico Medical, Inc.Inventors: Qiyong Peter Liu, Junqing Cui, Rud Karly Lucien, Ryan Carney, Jihae Sohn, Michelle Arya, Abdul W. Khan
-
Publication number: 20220040110Abstract: A method of treatment of plasma with a physiologically compatible spray dry stable acidic substance (SDSAS) prior to or contemporaneously with spray drying of the plasma that results in greater recovery and greater long-term stabilization of the dried plasma proteins as compared to spray dried plasma that has not be subject to the formulation method of the present invention, as well as compostions related to plasma dried by the methods of the present invention.Type: ApplicationFiled: October 22, 2021Publication date: February 10, 2022Applicant: Velico Medical Inc.Inventors: Qiyong Peter Liu, Junqing Cui, Rud Karly Lucien, Ryan Carney, Jihae Sohn, Michelle Arya
-
Publication number: 20210290545Abstract: A method of treatment of plasma with a physiologically compatible spray dry stable acidic substance (SDSAS) prior to or contemporaneously with spray drying of the plasma that results in greater recovery and greater long-term stabilization of the dried plasma proteins as compared to spray dried plasma that has not be subject to the formulation method of the present invention, as well as compositions related to plasma dried by the methods of the present invention.Type: ApplicationFiled: June 2, 2021Publication date: September 23, 2021Applicant: Velico Medical Inc.Inventors: Qiyong Peter Liu, Junqing Cui, Rud Karly Lucien, Ryan Carney, Jihae Sohn, Michelle Arya
-
Patent number: 11052045Abstract: A method of treatment of plasma with a physiologically compatible spray dry stable acidic substance (SDSAS) prior to or contemporaneously with spray drying of the plasma that results in greater recovery and greater long-term stabilization of the dried plasma proteins as compared to spray dried plasma that has not be subject to the formulation method of the present invention, as well as compositions related to plasma dried by the methods of the present invention.Type: GrantFiled: December 19, 2016Date of Patent: July 6, 2021Assignee: Velico Medical, Inc.Inventors: Qiyong Peter Liu, Junqing Cui, Rud Karly Lucien, Ryan Carney, Jihae Sohn, Michelle Arya
-
Publication number: 20190246629Abstract: The present invention relates to methods and compositions for reducing sialidase activity and inhibiting bacterial proliferation of one or more bacteria in a platelet product preparation from one or more donors. In general, the method includes contacting the platelet product preparation with an amount of a sialidase inhibitor, to thereby obtain a sialidase inhibitor-treated platelet product preparation. Sialidase activity is reduced and the proliferation of one or more bacteria is inhibited, as compared to a platelet product preparation not subjected to the sialidase inhibitor treatment.Type: ApplicationFiled: April 22, 2019Publication date: August 15, 2019Applicants: Velico Medical, Inc., The Brigham and Women's Hospital, Inc.Inventors: Qiyong Peter Liu, Karin Hoffmeister, Robert Sackstein
-
Publication number: 20190203175Abstract: The present invention relates to a platelet protection solution (PPS) having an amount of one or more ?-galactosidase inhibitors with or without an amount of one or more sialidase inhibitors, and optionally one or more glycan-modifying agents; and one or more of PPS components that include a salt, a citrate source, a carbon source, or any combination thereof.Type: ApplicationFiled: September 10, 2018Publication date: July 4, 2019Applicant: Velico Medical, Inc.Inventor: Qiyong Peter Liu
-
Publication number: 20190200602Abstract: The present invention relates to a platelet additive solution (PAS) having an amount of one or more ?-galactosidase inhibitors with or without an amount of one or more sialidase inhibitors, and optionally one or more glycan-modifying agents; and one or more of PAS components that include a salt, a citrate source, a carbon source, or any combination thereof.Type: ApplicationFiled: March 5, 2019Publication date: July 4, 2019Applicants: Velico Medical, Inc., The Brigham and Women's Hospital, Inc.Inventors: Qiyong Peter Liu, Karin Hoffmeister, M, Robert Sackstein
-
Patent number: 10271541Abstract: The present invention relates to a platelet additive solution (PAS) having an amount of one or more ?-galactosidase inhibitors with or without an amount of one or more sialidase inhibitors, and optionally one or more glycan-modifying agents; and one or more of PAS components that include a salt, a citrate source, a carbon source, or any combination thereof.Type: GrantFiled: February 17, 2017Date of Patent: April 30, 2019Assignees: Velico Medical, Inc, The Brigham and Women's Hospital, Inc.Inventors: Qiyong Peter Liu, Karin Hoffmeister, Robert Sackstein
-
Publication number: 20180000066Abstract: The present invention relates to a platelet protection solution (PPS) having an amount of one or more ?-galactosidase inhibitors with or without an amount of one or more sialidase inhibitors, and optionally one or more glycan-modifying agents; and one or more of PPS components that include a salt, a citrate source, a carbon source, or any combination thereof.Type: ApplicationFiled: September 13, 2017Publication date: January 4, 2018Inventors: Qiyong Peter Liu, Karin Hoffmeister, Robert Sackstein
-
Publication number: 20170370952Abstract: The present invention relates to a reconstitution solution for spray dried plasma having a non-anticoagulant compound that does not bind calcium. When the reconstitution solution of the present invention is mixed with spray dry plasma, the reconstituted plasma mediates platelet adhesion and aggregation about the same as or greater than the starting plasma prior to spray drying. The present invention also relates to an assay for determining platelet adhesion and aggregation using microfluidic flow cell system having a shear flow. The assay assesses labeled whole blood samples having reconstituted plasma having spray dried plasma and a reconstitution solution; platelets; and red blood cells. After inducing a shear flow under conditions suitable for clot formation, coverage area of the platelets, intensity of the platelets, morphology, or a combination thereof is detected to determine platelet accumulation (e.g., platelet adhesion and aggregation).Type: ApplicationFiled: April 7, 2017Publication date: December 28, 2017Inventors: Qiyong Peter Liu, Ryan Christopher Carney, Andrew Peter Cap, Michael Adam Meledeo